A comparison of latanoprost monotherapy with a combination therapy of timolol/dorzolamide in patients with primary open-angle glaucoma

Annals of Ophthalmology

Volumn 38, Issue 2, 2006, Pages 111-115

  Çaça, Ihsan ^a   Simsek, Hüseyin ^a   Ünlü, Kaan ^a   Ari, Seyhmus ^a   Keklikçi, Ugur ^a  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DORZOLAMIDE; LATANOPROST; TIMOLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EYE BURNING; EYE COLOR; EYELASH; FEMALE; HUMAN; HYPEREMIA; HYPERPIGMENTATION; HYPERTRICHOSIS; INTRAOCULAR FOREIGN BODY; INTRAOCULAR PRESSURE; IRIS DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; THERAPY EFFECT; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; DRUG THERAPY, COMBINATION; EYE COLOR; EYELASHES; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; HYPEREMIA; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PAIN; PROSTAGLANDINS F, SYNTHETIC; PRURITUS; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 33749139972     PISSN: 15304086     EISSN: None     Source Type: Journal    
DOI: 10.1385/AO:38:2:111     Document Type: Article

References (27)

1. O'Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002;133:836-837.
2. Garcia Sanchez J. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension - a three-month randomised study. Spanish Latanoprost Study Group. Eur J Ophthalmol 2000;10:198-204.
3. Hoyng PF, van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs 2000;59:411-434.
4. Balfour JA, Wilde MI. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging 1997;10:384-403.
5. Patel SS, Spencer CM. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 1996;9:363-378.
6. Emmerich KH. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension. A 3-month randomised study. Graefes Arch Clin Exp Ophthalmol 2000;238:19-23.
7. Fechtner RD, Airaksinen PJ, Getson AJ, et al. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004;82:42-48.
8. Honrubia FM, Larsson LI, Spiegel D. European latanoprost study group. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. Acta Ophthalmol Scand 2002;80:635-641.
9. Toshino A, Okamoto S, Shimamura I, et al. The mechanism of corneal epithelial disorder induced by prostaglandin F2 alpha isopropyl unoprostone. Nippon Ganka Gakkai Zasshi 1998;102:101-105.
10. Ito K, Goto R, Matsunaga K, Sugimoto K, Uji Y. Switch to latanoprost monotherapy from combined treatment with beta-antagonist and other antiglaucoma agents in patients with glaucoma or ocular hypertension. Jpn J Ophthalmol 2004;48:276-280.
11. Rulo AH, Greve EL, Geijssen HC, Hoyng PF. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology 1996;103:1276-1282.
12. Cantor L. Glaucoma, American Academy of Ophthalmology Basic and Clinical Course, San Francisco, 2000;10:111-112.
13. Villumsen J, Alm A. The effect of adding prostaglandin F2 alphaisopropylester to timolol in patients with open angle glaucoma. Arch Ophthalmol 1990;108:1102-1105.
14. Nordmann JP, Soderstrom M, Rouland JF, Malecaze F. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group. Br J Ophthalmol 2000;84:181-185.
15. Perry CM, McGavin JK, Culy CR, Ibbotson T. Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging 2003;20:597-630.
16. Hedman K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol 2002;47:S65-76.
17. Fechtner R, Clineschmidt C, Getson A, Adamsons I. A three month, parallel, randomized, observer-masked multicenter study comparing Cosopt (TM) to Xalatan (TM) in patients with elevated IOP. Invest Ophthalmol Vis Sci 1999;40:S665.
18. Fechtner RD, McCarroll KA, Lines CR, Adamsons IA. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. J Ocul Pharmacol Ther 2005;21:242-249.
19. Konstas AG, Kozobolis VP, Tersis I, Leech J, Stewart WC. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Eye 2003;17:41-46.
20. Bayer A, Weiler W, Oeverhaus U, et al. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. J Ocul Pharmacol Ther 2004;20:470-478.
21. Sponsel WE, Paris G, Trigo Y, Pena M. Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma. Am J Ophthalmol 2002;134:552-559.
22. Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 1996;114:929-932.
23. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124:544-547.
24. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol 1999;127:602-604.
25. Kaufman HE, Varnell ED, Thompson HW. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol 1999;127:531-536.
26. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998;126:37-41.
27. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998;105:263-268.